A Phase II Trial of LBH589 in Patients With Metastatic Medullary Thyroid Cancer and Radioactive Iodine Resistant Differentiated Thyroid Cancer.
Phase of Trial: Phase II
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Panobinostat (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 11 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
- 11 May 2015 Planned End Date changed from 1 Jul 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record
- 01 Dec 2014 Planned End Date changed from 1 Aug 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.